P316 Inflammatory Bowel Disease and malignancy: What are the predictors of malignancy in Inflammatory Bowel Disease?

Abstract

Abstract Background The aim of this study is to investigate the incidence of malignancy in patients with inflammatory bowel disease (IBD) followed up in a tertiary reference center. Methods IBD patients who were with at least 6 months of follow-up between the 1991-2022 from the gastroenterology clinic were evaluated retrospectively. Descriptive statistics for continuous variables in the study; expressed as mean (mean), standard deviation (SD), minimum, maximum, number (n) and percent (%). “Independent T-test” was used to compare continuous measurement values according to categorical groups. Chi-square test was used to determine the relationships between categorical variables. Results There were 696 patients in the study totally. 319 (45.83%) of these patients were female. Mean age of the patients were 48.27±14.58 years. IBD type was changed as; 307 (44.1%) had ulcerative colitis, 377 (54.1%) had Crohn's disease, 12 (1.8%) had indeterminate colitis. Before the diagnosis of IBD, 8 patients (1.1%) had a history of malignancy. The prevalence of malignancy after the diagnosis of IBD was 13 (1.86%). The characteristic of these 13 patients are described in Table 1. When the relationship between malignancy and gender, age, body mass index (BMI), disease age, and disease type in patients who developed malignancy in inflammatory bowel disease was examined, a statistically significant relationship was found in the elderly and those with high BMI (p=0.0019, p=0.004, respectively). When we look at the relationship between the risk of developing malignancy in IBD and the age of the disease at 10 and 8 years period, it was seen that there was no statistically significant relationship (p=0.245, p=0.343). When the patients who developed malignancy in IBD were compared in terms of the immunomodulators and biological agents used by the patients who did not develop malignancy, there was no statistical difference between the two groups (p>0.05). (Fig.1 Graphical abstract). Fig.1 Graphical abstract Conclusion Higher BMI and being older age found to be risk for the development of malignancy in IBD patients, although no relationship was found with the use of immunomodulator, biological agents, or disease type. The risk of malignancy, especially colorectal cancers, is increased in IBD. Therefore, close follow-up of these patients is important.